Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Safety and efficacy of resident-performed SION goniotomy at the time of cataract surgery
Author Affiliations & Notes
  • Nikita Mokhashi
    Department of Ophthalmology, University of Chicago Pritzker School of Medicine, Chicago, Illinois, United States
  • Ian Patterson
    Department of Ophthalmology, University of Chicago Pritzker School of Medicine, Chicago, Illinois, United States
  • Mary Qiu
    Department of Ophthalmology, University of Chicago Pritzker School of Medicine, Chicago, Illinois, United States
  • Footnotes
    Commercial Relationships   Nikita Mokhashi None; Ian Patterson None; Mary Qiu Allergan, Code C (Consultant/Contractor)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 3471. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nikita Mokhashi, Ian Patterson, Mary Qiu; Safety and efficacy of resident-performed SION goniotomy at the time of cataract surgery. Invest. Ophthalmol. Vis. Sci. 2024;65(7):3471.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To report safety and outcomes of resident performed Sion goniotomy at the time of cataract surgery (phaco-SION).

Methods : We conducted a retrospective chart review of all patients that underwent resident-performed SION goniotomy at the time of cataract surgery at the University of Chicago from 9/1/2022 to 9/30/2023. All residents were in their PGY-3 or PGY-4 year. Eyes with prior traditional glaucoma surgery or cyclophotocoagulation were excluded. The primary aim was to determine whether resident-performed SION goniotomy demonstrated operating times and complication rates similar to those of Kahook Dual Blade goniotomy. A secondary aim was to report short-term outcomes (IOP and number of IOP-lowering medications at postoperative month 3).

Results : There were 38 eyes from 35 patients that underwent resident-performed SION goniotomy at the time of cataract surgery. Demographic and clinical characteristics are shown in Table 1. The cataract surgery component was also performed by the resident in 13/38 (34%) cases. Of the 38 Sion cases, 36 (95%) were performed by PGY3 residents, and 2 (5%) by PGY4 residents. The average operating time for phaco-SION was 50.7 minutes. Hyphema occurred in 1 (3%) eye at post-operative day (POD) 1, 5 (13%) eyes at post-operative week (POW) 1, and 0 (0%) eyes at post-operative month (POM) 1. Of the 5 hyphemas at POW1, 2 were less than 0.5mm. Other complications included intraocular pressure (IOP) spike over 30 mmHg in 5 (13%) cases, cystoid macular edema in 3 cases (8%), and vitreous hemorrhage in 1 (3%) case. Of the 5 IOP spikes, 2 occurred on POD1, 2 on POM1, and 1 on POM2.5. IOP spikes were possibly related to use of durezol instead of prednisone. Vitreous hemorrhage was due to proliferative diabetic retinopathy. One eye underwent subsequent cyclophotocoagulation, and no eyes underwent subsequent incisional glaucoma surgery. There were 23/38 (61%) of eyes that reached 3 month follow-up to date. Preoperatively, the mean IOP was 16.0 mmHg on 2.8 medications; at POM3, mean IOP was 13.9 mmHg on 2.4 medications.

Conclusions : Resident-performed SION goniotomy had a safety and short-term efficacy profile similar to what is reported in the resident-performed and attending-performed KDB goniotomy literature. SION goniotomy can be safely and effectively performed by PGY-3 and PGY-4 residents. Training residents in minimally invasive glaucoma surgery should be encouraged.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×